The Evolving CGM Landscape and GS1’s Strategic Expansion in Europe

  1. CGM Industry Trends: From Diabetes Care to Holistic Health Management
The global Continuous Glucose Monitoring (CGM) market is undergoing a paradigm shift. While early adoption focused on Type 1 diabetes, advancements in non-invasive technology and cost reduction are driving demand among Type 2 diabetics and even non-diabetic populations812. Key trends include:
  • Expansion to Non-Diabetic Users: Devices like Abbott’s Lingo target metabolic health optimization, offering insights into glucose responses to diet, exercise, and sleep.
  • OTC Accessibility: Over-the-counter CGM products are emerging, empowering users to monitor glucose without prescriptions.
The GS1 CGM, developed by SIBIONICS, aligns with these trends. Its non-invasive sensor and long-term wearability make it ideal for both diabetic management and preventive health monitoring16.
  1. Europe’s CGM Market: Growth Drivers and GS1’s Entry
Europe represents a high-growth CGM market, driven by rising diabetes prevalence and demand for non-invasive solutions. For instance, Saudi Arabia’s diabetic population exceeds 4.2 million, creating urgent needs for advanced glucose management tools.
GS1’s Strategic Success in the Middle East: SIBIONICS partnered with ProMedEx to launch GS1 in Saudi Arabia, addressing local healthcare gaps through:
  • Real-Time Data Integration: Enables remote monitoring for physicians, critical in regions with limited medical infrastructure.
  • Cost-Effective Design: Eliminates recurring expenses for test strips, reducing long-term patient costs.
This expansion mirrors Europe’s demand for innovative CGM solutions. Analysts predict the European CGM market will grow at a CAGR of 12.3% through 2027, with non-invasive devices like GS1 leading adoption.
  1. AGP Reports: Bridging Data and Clinical Decisions
The Ambulatory Glucose Profile (AGP) is a cornerstone of CGM utility. For GS1 users, AGP metrics like Time-in-Range (TIR) and glycemic variability provide actionable insights:
  • TIR Optimization: Studies show 86.8% TIR in Type 2 diabetics using CGM, significantly reducing complication risks.
  • Personalized Interventions: Physicians leverage AGP data to tailor insulin dosing and lifestyle recommendations
By integrating AGP analytics, GS1 enhances both patient self-management and clinical outcomes, positioning it as a leader in data-driven diabetes care

 

Voltar para Controle de açúcar no sangue

você pode gostar Ver tudo

Beyond Diabetes: How CGM and Sibionics GS1 Can Benefit Non-Diabetics
The Importance of CGM in Diabetes Diagnosis and Management
The Role of Continuous Glucose Monitoring (CGM) in Enhancing Athletic Performance
Sistema de monitoramento contínuo de glicose SIBIONICS GS1 CGM SIBIONICS GS1 CGM Sistema de monitoramento contínuo de glicose por 14 dias Ofertas especiais de compra em massa - Sistema de monitoramento contínuo de glicose SIBIONICS GS1 CGM

Novo em folha

Sistema de monitoramento contínuo de glicose (CGM) SIBIONICS GS1

Leituras de sensores altamente precisas
Glicose contínua de 14 dias
Monitoramento Calibração Grátis
Sem digitalização
Relatórios AGP exportáveis
IP28 à prova d'água
Alarme de glicose personalizável
Aplicativo fácil de usar
Dados compartilháveis ​​de glicose em tempo real

Compre GS1